- Home
- REPL vs PFN Comparison
REPL vs PFN Comparison
Compare REPL & PFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REPL
- PFN
- Stock Information
- Founded
- REPL 2015
- PFN 2004
- Country
- REPL United States
- PFN United States
- Employees
- REPL N/A
- PFN N/A
- Industry
- REPL Biotechnology: Pharmaceutical Preparations
- PFN Finance/Investors Services
- Sector
- REPL Health Care
- PFN Finance
- Exchange
- REPL Nasdaq
- PFN Nasdaq
- Market Cap
- REPL 816.4M
- PFN 661.3M
- IPO Year
- REPL 2018
- PFN N/A
- Fundamental
- Price
- REPL $11.05
- PFN $7.47
- Analyst Decision
- REPL Strong Buy
- PFN
- Analyst Count
- REPL 4
- PFN 0
- Target Price
- REPL $17.00
- PFN N/A
- AVG Volume (30 Days)
- REPL 488.6K
- PFN 331.7K
- Earning Date
- REPL 11-12-2024
- PFN 01-01-0001
- Dividend Yield
- REPL N/A
- PFN 11.66%
- EPS Growth
- REPL N/A
- PFN N/A
- EPS
- REPL N/A
- PFN N/A
- Revenue
- REPL N/A
- PFN N/A
- Revenue This Year
- REPL N/A
- PFN N/A
- Revenue Next Year
- REPL $469.74
- PFN N/A
- P/E Ratio
- REPL N/A
- PFN N/A
- Revenue Growth
- REPL N/A
- PFN N/A
- 52 Week Low
- REPL $4.92
- PFN $5.94
- 52 Week High
- REPL $12.97
- PFN $7.58
- Technical
- Relative Strength Index (RSI)
- REPL 43.04
- PFN 46.81
- Support Level
- REPL $10.57
- PFN $7.32
- Resistance Level
- REPL $12.73
- PFN $7.49
- Average True Range (ATR)
- REPL 0.67
- PFN 0.06
- MACD
- REPL -0.16
- PFN -0.01
- Stochastic Oscillator
- REPL 20.00
- PFN 57.14
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.